Altogether, therapeutic drug monitoring (TDM) with concomitant ADA and trough level measurements detected ADA-mediated clinical LOR more frequently in IFX-treated (65/180, 36%) than in ADL-treated (29/141, 21%; P = 2.9 × 10−3) patients with IBD. Here, ADA is linked to inflammatory bowel disease.